Skip to main content
FDA committees discuss possible restrictions for high-dose opioids

The FDA's Anesthetic and Analgesia Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee started a two-day meeting to seek input from patients and health care experts on the clinical value and potential risks of higher opioid doses. The agency will use the feedback to determine whether higher opioid doses should be restricted or pulled from the market.

Full Story: